Related Experiment Videos
Peptichemio in advanced neuroblastoma.
Cancer Treatment Reports
|May 1, 1978
Summary
Peptichemio (PTC), a peptide-based chemotherapy, showed high initial response rates in children with advanced neuroblastoma. However, its long-term efficacy was limited by short remission durations and significant toxicity.
Area of Science:
- Oncology
- Pharmacology
- Pediatric Medicine
Background:
- Neuroblastoma is a common pediatric cancer.
- Effective treatments for advanced neuroblastoma are crucial.
- Peptichemio (PTC) is a synthetic peptide-based chemotherapy agent.
Purpose of the Study:
- To evaluate the efficacy and toxicity of Peptichemio (PTC) in previously untreated children with advanced neuroblastoma.
Main Methods:
- 18 children with advanced neuroblastoma received PTC intravenously at 1-1.5 mg/kg/day for 1-3 cycles.
- Treatment involved 5-6 consecutive days of administration per cycle.
Main Results:
- 92% of patients (11/12) showed objective and subjective improvement.
- Complete remission was achieved in 2 patients.
- Median remission duration was 4 months; median overall survival was 6 months.
- Primary toxicities included bone marrow depression, phlebosclerosis, nausea, vomiting, and alopecia.
Conclusions:
- PTC demonstrated high initial response rates in pediatric neuroblastoma.
- Long-term outcomes were limited by short remission duration and survival.
- Profound thrombocytopenia and severe phlebosclerosis restrict chronic PTC use.